SCL Science Inc.
Financials
Valuation Metrics
SCL Science Inc.'s Market Cap is ₩748B. At end of 2025 it was ₩800B. Ranked #1394 of 2,410 in KR market (top 58%), #783 of 1,631 on KOSDAQ (top 48%), #50 of 94 in Health Care Equipment & Services (top 53%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 74.81B KRW | KR#1,394/2,410 Sec#50/94 |
| Revenue | 30.50B KRW | KR#2,021/2,410 Sec#66/94 |
| Net Income | -3.83B KRW | KR—/2,410 Sec—/94 |
| Total Assets | 78.90B KRW | KR#1,938/2,410 Sec#62/94 |
| Net Assets | 22.90B KRW | KR#2,252/2,410 Sec#83/94 |
| Employees | 63 | KR#1,934/2,410 Sec#79/94 |
| Value | ||
| P/B | 3.27x | KR#2,173/2,410 Sec#78/94 |
| P/S | 2.45x | KR#1,947/2,410 Sec#61/94 |
| FCF Yield | -4.07% | KR—/2,410 Sec—/94 |
| Profitability | ||
| ROE | -16.74% | KR#2,051/2,410 Sec#74/94 |
| ROA | -4.86% | KR#1,923/2,410 Sec#64/94 |
| Op. Margin | -3.02% | KR#1,776/2,410 Sec#54/94 |
| Revenue Growth | 225.88% | KR#34/2,410 Sec#4/94 |
| Financial Health | ||
| Debt Ratio | 244.58% | KR#2,196/2,410 Sec#88/94 |
| Total Debt | 25.83B KRW | KR#1,290/2,410 Sec#35/94 |
| FCF | -3.05B KRW | KR#1,391/2,410 Sec#46/94 |
| Cash | 3.69B KRW | KR#2,110/2,410 Sec#83/94 |
| Current Ratio | 0.57x | KR#2,094/2,410 Sec#88/94 |
| Performance | ||
| 1Y Return | -13.48% | KR#859/2,410 Sec#21/94 |
| 1M Return | -17.94% | KR#1,824/2,410 Sec#78/94 |
| From 52W High | -26.87% | KR#315/2,410 Sec#9/94 |
| 1Y MDD | -45.14% | KR#744/2,410 Sec#25/94 |
| Trading | ||
| Volume | 73,294 shares | KR#531/2,410 Sec#21/94 |
| Trading Value | 156.2M KRW | KR#1,060/2,410 Sec#42/94 |
| Foreign Own. | 0.50% | KR#2,198/2,410 Sec#83/94 |
| Per Share | ||
| EPS | -110 KRW | KR—/2,410 Sec—/94 |
| BPS | 658 KRW | KR#2,360/2,410 Sec#91/94 |
Company Info
SCL Science, established in 2010 and listed on KOSDAQ in 2019, is a bio venture company. It primarily develops and produces medical hemostatic agents using biomimetic technology inspired by mussel adhesion, alongside operating bio-logistics and data platform-based digital healthcare businesses. The company is developing a range of hemostatic products applicable to patients with blood coagulation disorders and expanding its product portfolio with polymer modification technology, growing into a healthcare company. SCL Science is headquartered in Yeongdeungpo-gu, Seoul.